BioSpace News Archive

Expanded footprint gives 4 out of 5 Medicare-eligible beneficiaries access to an Aetna Medicare Advantage plan

First-of-its-kind trial will test the efficacy of cannabis as a treatment for taxane-induced peripheral neuropathy, which affects 67 percent of women undergoing breast cancer treatment

VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will present new immuno-oncology data in a presentation titled, “eVLPs as an Antigen Delivery & Immunomodulatory Platform in Cancer,” at the World Vaccine Congress Europe to be held October 29-31, 2019, in Barcelona.

TraceLink Inc., the world’s largest integrated digital supply network providing real-time information sharing for better patient outcomes, today announced that Bharath Sundararaman has joined the Company as General Manager of its Intelligent Supply Network business area.

Swiss pharmaceutical company Primex Pharmaceuticals AG announces the appointment of Mr. Dan Spacie, as Global Commercial Head to the Executive Management Team led by CEO Alan Knox.

Varian (NYSE: VAR) today announced it was selected by The Ohio State University to equip a new multi-room proton therapy center in central Ohio with the ProBeam 360° system.

Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced the appointment of Kevin E. McCracken, B.S., M.B.A., as Senior Vice President of Operations.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that nine abstracts, including several associated with vadadustat and Auryxia® (ferric citrate), have been accepted for presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that BTI’s Senior Vice President and Chief Medical Officer, Vincent O’Neill, M.D., will present the first clinical results on the safety and tolerability of BXCL701

New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc (Nasdaq: HZNP), will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31.